C. Wolf

发表

Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.

M. Rezai, P. Fasching, L. Häberle, 2018, European journal of cancer.

Lipid-Lowering Therapy in Patients with Peripheral Arterial Disease

A. Shah, R. Ebrahimi, E. Toggart, 2004, Journal of cardiovascular pharmacology and therapeutics.

Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients

M. Rezai, P. Fasching, L. Häberle, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients

M. Lux, M. Beckmann, P. Fasching, 2014, BMC Cancer.

Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer.

W. Eiermann, A. Wolf, M. Schuler, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study.

M. Rezai, M. Beckmann, P. Fasching, 2014, Geburtshilfe und Frauenheilkunde.

Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study

M. Rezai, M. Beckmann, P. Fasching, 2019, BMC Cancer.

Interest in Integrative Medicine Among Postmenopausal Hormone Receptor–Positive Breast Cancer Patients in the EvAluate-TM Study

M. Rezai, M. Beckmann, P. Fasching, 2016, Integrative cancer therapies.

Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study

M. Rezai, M. Beckmann, P. Fasching, 2019, BMC Cancer.

Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients

M. Lux, M. Beckmann, P. Fasching, 2019, International journal of cancer.

Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer

M. Lux, M. Beckmann, P. Fasching, 2019, Breast Cancer Research and Treatment.

Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients

M. Lux, M. Beckmann, P. Fasching, 2020, Breast.

Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study.

M. Rezai, M. Beckmann, P. Fasching, 2016, Breast care.

FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients

M. Lux, M. Beckmann, P. Fasching, 2014, BMC Cancer.

Cost-Effectiveness of Varenicline Compared to Placebo as an Aid to Smoking Cessation in Patients with Cardiovascular Disease

R. Hettle, W. Oaks, K. Wilson, 2012 .

Zafirlukast Induces VHL- and HIF-2α-Dependent Oxidative Cell Death in 786-O Clear Cell Renal Carcinoma Cells

Sjoerd J. L. van Wijk, C. Wolf, Sonja Smith, 2022, International journal of molecular sciences.

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study.

L. Zelek, A. Ballestrero, L. Fallowfield, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.